Product Description
Telmisartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, telmisartan relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart. Telmisartan is used alone or together with other medicines to treat high blood pressure (hypertension). Telmisartan is also used to lower the risk of heart attacks or stroke in patients 55 years of age and older who have diabetes or heart problems. (Sourced from: https://www.mayoclinic.org/drugs-supplements/telmisartan-oral-route/description/drg-20067196)
Mechanisms of Action: ARB Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, Korea, New Zealand, Nigeria, Poland, Sri Lanka, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Hypertension|Type 2 Diabetes
Phase 2: Panic Disorder
Phase 1: Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| THP-001-031 | P3 |
Not yet recruiting |
Hypertension|Type 2 Diabetes |
2026-06-01 |
|
| HB-PD-002 | P2 |
Not yet recruiting |
Panic Disorder |
2026-01-01 |
|
| THP-001-001 | P1 |
Completed |
Hypertension|Type 2 Diabetes |
2023-11-09 |
|
| GMRx2_PCT | P3 |
Completed |
Hypertension |
2023-09-18 |
95% |
| GMRx2_PCT | P3 |
Completed |
Hypertension |
2023-09-18 |
95% |